Compare · CYTK vs JNJ
CYTK vs JNJ
Side-by-side comparison of Cytokinetics Incorporated (CYTK) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYTK and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $610.38B, about 68.7x CYTK ($8.89B).
- Over the past year, CYTK is up 6.1% and JNJ is up 32.3% - JNJ leads by 26.2 points.
- JNJ has been more active in the news (16 items in the past 4 weeks vs 7 for CYTK).
- Both have 25 recent analyst ratings on file.
- Company
- Cytokinetics Incorporated
- Johnson & Johnson
- Price
- -
- -
- Market cap
- $8.89B
- $610.38B
- 1M return
- -11.38%
- -5.45%
- 1Y return
- +6.08%
- +32.25%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 7
- 16
- Recent ratings
- 25
- 25
Cytokinetics Incorporated
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest CYTK
- SEC Form 4 filed by Cytokinetics Incorporated
- Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
- SEC Form 4 filed by Cytokinetics Incorporated
- Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
- Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
- President & CEO Blum Robert I sold $490,950 worth of shares (7,500 units at $65.46) and exercised 7,500 shares at a strike of $10.60 (SEC Form 4)
- EVP Research & Development Malik Fady Ibraham exercised 3,500 shares at a strike of $7.80 and sold $239,015 worth of shares (3,500 units at $68.29) (SEC Form 4)
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Landry Robert E sold $72,130 worth of shares (1,000 units at $72.13), decreasing direct ownership by 11% to 8,184 units (SEC Form 4)
- President & CEO Blum Robert I sold $7,340,010 worth of shares (105,426 units at $69.62) as part of a pre-agreed trading plan, gifted 99,276 shares, received a gift of 97,926 shares and exercised 7,500 shares at a strike of $10.60, decreasing direct ownership by 26% to 278,544 units (SEC Form 4)
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause